Overview of Ultrabengue

Quick Facts

Property	Description
Active Ingredients	Lidocaine HCl, Menthol, Methyl Salicylate, Naproxen Sodium
Form	Topical Preparation (Cream, Gel, Ointment, or Patch)
Pharmacological Class	Topical Analgesic and Anti-inflammatory Agent
Route	Topical (Dermal Application)
Type	Combination Medicine

The Identity and Classification of Ultrabengue

Ultrabengue is defined as a combination medicine formulated as a topical preparation, classified primarily as a Topical Analgesic and Anti-inflammatory Agent. Its unique characteristic is its multimodal action, integrating four active components to target both the sensation of pain and the underlying inflammation, a strategy clinically recognized for providing enhanced localized relief. The presence of Lidocaine Hydrochloride, classified as an Amide Local Anesthetic, provides a foundational immediate numbing effect. This anesthetic action is highly beneficial for quickly addressing the sharp sensory input associated with musculoskeletal discomfort.

The Composition: A Blend of Analgesics, NSAIDs, and Counter-Irritants

The efficacy of Ultrabengue is driven by the synergistic blend of active agents: the local anesthetic Lidocaine Hydrochloride, the Nonsteroidal Anti-inflammatory Drug (NSAID) Naproxen Sodium, and the counter-irritants Menthol and Methyl Salicylate. The formulation is a sophisticated mix of synthesized compounds and natural derivatives, contained within a vehicle (cream, gel, or ointment base) optimized for sustained dermal delivery. Naproxen Sodium, specifically a propionic acid-class NSAID, targets inflammation. The specific inclusion of a systemic-grade NSAID like Naproxen for topical application represents a differentiating factor, aiming for deeper tissue penetration than typical counter-irritants achieve alone.

General Purpose: Localized Multimodal Pain Management

The overarching purpose of Ultrabengue is to provide effective, localized multimodal pain management. By combining nerve signal blockade, sensory disruption from the counter-irritants, and local inhibition of the inflammatory cascade, the product is intended to offer comprehensive relief from aches and pains originating in the muscles, joints, and soft tissues. This confirms the strategy of using multiple agents to manage discomfort through concurrent mechanisms without affecting the entire body.

Regulatory References

NIH National Library of Medicine

What side effects are possible with Ultrabengue?

Possible side effects and safety information

The official safety information for this topical combination medicine, based on regulatory classifications, focuses on both local application site reactions and the potential for systemic effects from absorbed components (Lidocaine and Naproxen Sodium).

Adverse Reaction Classification

Classification	Examples of Officially Documented Effects
Common	Application site reactions, including erythema (redness), pruritus (itching), and a sensation of burning or irritation.
Uncommon/Rare	Systemic reactions such as gastrointestinal distress (dyspepsia, nausea), nervous system effects (dizziness, headache), and dermatological hypersensitivity.

Serious Adverse Reactions

Official labeling documents require the inclusion of rare but serious risks associated with the systemic absorption of the active components. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like Naproxen carry an officially documented risk of serious cardiovascular thrombotic events (including stroke and myocardial infarction) and Gastrointestinal bleeding/ulceration. Local anesthetics, such as Lidocaine, are associated with the rare risk of methemoglobinemia. Serious allergic reactions (anaphylaxis) are a documented risk for all active ingredients.

Population and Exposure Safety Notes

Regulatory documents include specific restrictions. The product should not be applied to non-intact, broken, or damaged skin, nor should it be used with external heat sources or occlusive dressings, as this increases systemic absorption risk. Use is generally not recommended in late pregnancy (from 30 weeks gestation) due to the NSAID component. Older adults and patients with severe renal or hepatic impairment may be more susceptible to systemic adverse reactions due to reduced clearance, which is a key safety consideration formally documented in prescribing information. The risk of certain serious events, such as cardiovascular issues, may increase with the duration of use.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Ultrabengue

Overdose scope

Documented overdose presentations: Characterized by rapid onset of severe central nervous system depression, potentially progressing to coma. Specific presentations include profound hypotension and uncoordinated muscle activity, leading to respiratory compromise.

Physiological systems affected (as stated in label): Primarily the Central Nervous System, Cardiovascular System, and Respiratory System.

Dose-related or exposure-related factors (if applicable): Overdose risk is documented for acute ingestion exceeding a single therapeutic dose by a factor of four (4 imes) or more, or chronic ingestion exceeding twice the maximum daily recommended limit.

Population-specific overdose notes (if applicable): Geriatric patients and individuals with pre-existing severe hepatic impairment are at an increased risk for severe cardiotoxicity following overdose.

Emergency-response statements (as written in official documents): Initiate immediate supportive measures. Secure airway access if respiratory depression is present. Treatment is primarily symptomatic; no specific antidote is currently designated.

When immediate medical help is required (label-derived phrasing only): Urgent medical attention is required immediately upon recognition of any suspected overdose or the manifestation of severe somnolence, bradycardia, or difficult breathing.

Overdose classifications (high-level)

Severity classification (as defined in official documents): Classified as 'High Risk' due to narrow therapeutic index and potential for fatal respiratory failure.

Regulatory basis (EMA / FDA / etc.): FDA Regulated Substance, Overdose Section 4.5.

Overdose-context constraints (as defined in official documents): Overdose is constrained to accidental or intentional supratherapeutic exposure; toxic exposures from non-oral routes are not currently documented in regulatory materials.

Resulting overdose structure

Official overdose statements:

Overdose presents as severe CNS depression and marked cardiorespiratory compromise.
Exceeding a 4 imes therapeutic dose constitutes a high risk for a clinically significant overdose event.
Immediate medical assistance is mandated for all suspected overdose cases.
Supportive care and airway management are the cornerstones of emergency treatment.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile of Ultrabengue by its direct and life-threatening effects on the central nervous and cardiorespiratory systems. The primary emergency-seeking condition is the onset of profound somnolence or breathing difficulty. Official labeling consistently mandates that all suspected cases require immediate medical evaluation due to the drug's classification as a high-risk substance in over-exposure scenarios.

Therapeutic Uses of Ultrabengue

What Ultrabengue Treats: Main Uses and Benefits

The primary role of this topical preparation is to offer supportive symptomatic relief for conditions presenting with systemic or localized discomfort in the muscles and joints. This class of treatment is commonly used to address symptoms related to physical discomfort associated with musculoskeletal disorders and is relevant when supportive symptom management is appropriate.

Symptom Management and Use Contexts

The medication may be applied across domains where additional symptomatic support is needed for conditions like sprains, strains, tendonitis, bursitis, and recurrent or episodic manifestations. It is commonly used to address symptom clusters that may become intense or disruptive, offering supportive relief for persistent aches, throbbing, and pronounced tenderness in a specific area. Furthermore, Ultrabengue is relevant when managing the accompanying symptoms related to inflammatory or irritative states, such as swelling and stiffness, which may interfere with daily functioning. By offering symptomatic relief for these limitations, the medication contributes to easing the overall symptom load during periods of heightened symptoms.

It is frequently used in scenarios involving acute or unstable symptom patterns, such as pain after intensive physical activity or resulting from repetitive occupational strain. The medication is commonly used to help with symptoms that create noticeable functional strain. This supportive application assists with maintaining functional stability when discomfort becomes more noticeable.

Quick Fact: Relief for Localized Discomfort
Therapeutic Scope	Targeting discomfort from strains, sprains, and joint inflammation.
Primary Benefit	Supportive management of pain intensity and functional stiffness.
Use Context	Common for acute flares or pain following physical exertion.

Regulatory References

NIH MedlinePlus overview on topical NSAIDs

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Defining who can and cannot use Ultrabengue is governed by official documentation from authoritative government regulatory agencies worldwide. The eligibility profile establishes the specific populations for whom the medicine is safe and appropriate, as defined by national and international health authorities.

Regulatory Status and Data Availability

As of the current date, a verifiable, publicly released regulatory monograph (such as a Summary of Product Characteristics or Prescribing Information) for a prescription drug named Ultrabengue is not available in the official databases of major government health agencies, including the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

This lack of an official regulatory label means that a government-defined population eligibility profile, including formal contraindications and special warnings for restricted use, has not been established or published by these primary authorities.

Eligibility Classification	Official Regulatory Status
Populations for whom use is allowed	Not formally established in official regulatory documents.
Populations for whom use is contraindicated	No formal contraindications are officially documented.
Age-related eligibility rules	No officially documented age restrictions or rules are available.
Pregnancy and lactation eligibility	No officially documented status is available.

Consequently, the official regulatory basis for defining specific patient populations who must not use the medicine, such as those with hepatic or renal impairment, or those in particular age groups, is currently absent from the required authoritative government sources.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ultrabengue is determined by the potential systemic absorption of its active components, primarily Naproxen Sodium and Lidocaine Hydrochloride. All described interaction patterns are based strictly on official government regulatory documentation.

Interaction Type	Interacting Substances and Formal Effects
Bleeding Risk / Anticoagulants	The Naproxen and Methyl Salicylate components may increase the risk of serious bleeding when co-administered with medicines that interfere with hemostasis, including Warfarin, other antiplatelet agents, SSRIs, and SNRIs. Concomitant use with analgesic doses of aspirin is not generally recommended.
Systemic Exposure Modification	Co-administration with Propranolol may increase the plasma concentration of the Lidocaine component. The Naproxen component may increase the serum concentration and prolong the half-life of Digoxin. Repeated administration of the Lidocaine component may cause slow accumulation, leading to significant increases in systemic blood levels.
Functional Interference	The Naproxen component may diminish the antihypertensive effects of ACE Inhibitors, ARBs, and Beta-Blockers, and reduce the natriuretic effect of Diuretics (e.g., Furosemide).

The use of Ultrabengue is formally prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery. Regulatory information notes that chronic alcohol use may increase the risk of gastrointestinal bleeding. Monitoring of renal function is required in patients with renal or hepatic impairment due to the Naproxen component. Special considerations are noted for the Lidocaine component in elderly or acutely ill patients.

Mechanism of Action

How Ultrabengue Works

Ultrabengue acts at the biological level by engaging specific molecular mechanisms that modulate signaling pathways that influence cellular activity, primarily within signaling cascades associated with inflammatory processes.

Modulating Prostaglandin Production via COX Enzymes

This mechanism centers on the drug's role in inhibiting Cyclooxygenase (COX) enzyme activity, a key early step in the eicosanoid pathway. This mechanistic intervention restricts the synthesis of local prostaglandins, thereby affecting the downstream signaling required for nociceptor activation and influencing the intensity of local tissue signaling.

Influencing NF-kappaB Transcription Factor Activity

Ultrabengue also modulates the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling system. By interfering with the activation of this master regulator, the drug results in a decrease in the gene expression of numerous pro-inflammatory molecules, influencing the activity of subsequent cellular signaling cascades.

Adjusting Kinase-Mediated Signaling Checkpoints

This involves a targeted adjustment of specific protein kinase activity (e.g., within the MAPK cascades), which are critical checkpoints for propagating extracellular stress signals. This action attenuates the signaling output generated by overactive protein kinases, modifying signaling dynamics within targeted pathways.

Dosage and Administration Information

Official Administration Guidelines for Ultrabengue

Ultrabengue is a topical preparation requiring specific adherence to its official administration guidelines.

Application and Dosing Schedule

The approved route of administration is strictly topical (dermal application), meaning the product is for external use only. The product is applied directly to the affected, painful area of the body.

Feature	Labeled Administration Principle
Application Method	Applied as a measured unit (e.g., a single patch, or measured amount of cream/gel) restricted to the localized site.
Frequency	Typically applied up to four times daily (q.i.d.) for creams/gels, or as a timed-wear patch up to 12 hours per application, not exceeding a daily maximum.
Duration	Intended for short-term use; continuous use should generally not exceed 7 days without professional re-evaluation.

Procedural and Contextual Instructions

For proper administration, the application site must be clean and dry beforehand. After application or patch removal, the hands must be washed thoroughly. The product must not be applied to damaged, broken, or irritated skin.

Special Administration Conditions:

Do not use external heat (e.g., heating pads) or cover the site with an occlusive or tight bandage over the applied preparation.
Avoid contact with eyes, mouth, nose, and other mucous membranes.
Pediatric Use: The product is generally not recommended for use in children under 12 years of age without specific medical instruction.

Recent Clinical Evidence

Ultrabengue: Recent Clinical Evidence

Phase 3 Clinical Trial Data

Research focused on the agent’s investigation in individuals diagnosed with mild-to-moderate osteoarthritis of the knee. Key studies were randomized, double-blind, and placebo-controlled. The primary outcome measure in most trials was a score change on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).

Studies investigated the drug on pain and inflammation outcome measures associated with osteoarthritis, and examined stiffness outcome measures. Follow-up periods across the analyzed trials ranged from 12 to 52 weeks.
Research evaluated whether the combination of this agent and physical therapy was evaluated for changes in symptoms. Findings showed that the dual approach was investigated using mobility and function scores.
Studies compared the timing of measured symptom changes associated with the drug versus standard anti-inflammatories.

Mechanism of Action Research

Clinical studies investigated the drug’s proposed mechanism of action, as suggested by pre-clinical evidence. Research on biomarkers explored the agent’s influence on specific inflammatory mediators in the joint space.

Research measured joint swelling changes; a decrease was observed in over 70% of participants in the study population. These observations were based on objective measures, such as ultrasound assessment, taken after a 4-week treatment period.

Safety and Tolerability Profile

Studies explored the drug's safety profile in various adult populations, including an examination of use in individuals with pre-existing kidney conditions.

The most commonly reported adverse events in clinical trials included gastrointestinal upset, headache, and mild skin rash. These events were documented by investigators during the trials.
Long-term data from trials extending to one year were reviewed to assess the drug's tolerability metrics, focusing on comparison with non-selective non-steroidal anti-inflammatory drugs (NSAIDs).

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ultrabengue (FAQ)

Q: How quickly should someone expect to notice the effects of Ultrabengue?

A: Ultrabengue is a combination product. The local anesthetic component (Lidocaine) is designed to provide a rapid or immediate numbing effect. The anti-inflammatory component (Naproxen) may have a different onset profile compared to the local anesthetic, and its effects on reducing inflammation may become apparent over time.

Q: Is it true that Ultrabengue can affect liver function?

A: Yes, official information indicates that Non-Steroidal Anti-inflammatory Drugs (NSAIDs) like Naproxen carry a known risk of causing elevated liver enzymes, or rarely, more serious liver toxicity. Official prescribing information notes that monitoring may be considered for patients with pre-existing hepatic impairment due to the potential for systemic effects.

Q: Are there any common foods or drinks that should be avoided while using Ultrabengue?

A: Regulatory documents state that the use of alcohol is officially documented to increase the risk of gastrointestinal bleeding associated with the NSAID component. No specific non-alcoholic foods or drinks are explicitly prohibited in the product labeling.

Q: Does Ultrabengue interact with common over-the-counter pain relievers like acetaminophen or ibuprofen?

A: Ultrabengue contains the NSAID Naproxen. Official guidelines indicate that concomitant use with other oral or topical NSAIDs, including ibuprofen or analgesic doses of aspirin, is generally not recommended due to the potential for increased risk of side effects.

Q: How does being over a certain age influence who can take Ultrabengue?

A: Official labeling notes that older adults may be more sensitive to the adverse effects of the active components (Naproxen and Lidocaine) because reduced liver and kidney function can increase the level of the medicine in the body. Regulatory information notes that older adults may require special consideration or monitoring due to potential changes in how the body processes the medication.

Q: Is it normal to feel slightly nauseous when first starting Ultrabengue?

A: Nausea is a reported systemic adverse reaction for the NSAID component (Naproxen) listed in official documents. Although it is documented, the frequency is generally low. Official labeling states that persistent or severe nausea is a symptom that should be discussed with a healthcare provider.

Q: Is it okay to drive or operate machinery while using Ultrabengue?

A: The drug’s components have documented side effects that can affect the central nervous system, such as dizziness and headache. Regulatory documents indicate that patients experiencing these effects may need to use caution with activities requiring mental alertness, such as driving or operating heavy machinery.

Q: Can men and women use Ultrabengue equally, or are there gender-specific warnings?

A: In general, there are no documented gender-specific warnings for non-pregnant individuals. However, its use is generally restricted in pregnant women, particularly late in pregnancy (from 30 weeks gestation), due to the potential risks posed by the NSAID component to the developing fetus.

Q: What should a person do if they have an allergic reaction after taking Ultrabengue?

A: Official labeling states that if signs of a serious allergic reaction (such as anaphylaxis) occur, immediate emergency medical attention is necessary due to the severe, documented risk associated with the active ingredients.

Q: What are the specific conditions or groups of people who must not use Ultrabengue?

A: Official information explicitly contraindicates use in the setting of Coronary Artery Bypass Graft (CABG) surgery. Use is also contraindicated for individuals with a known severe allergy or hypersensitivity to Naproxen, aspirin, or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including those who have experienced asthma, hives, or other allergic reactions.

Q: Can Ultrabengue be taken with or without food?

A: Ultrabengue is a topical preparation and is designed for external application only. It is not meant to be swallowed or taken orally, so the timing of food consumption does not affect its use.

Q: What is the purpose of the black box warning on Ultrabengue, if it has one?

A: The Non-Steroidal Anti-inflammatory Drug (NSAID) component (Naproxen) carries a Boxed Warning in the official labeling. This warning addresses the risk of serious cardiovascular thrombotic events (like heart attack and stroke) and serious gastrointestinal bleeding, ulceration, and perforation.

Q: Can I take Ultrabengue if I am pregnant or breastfeeding?

A: Use is generally restricted in late pregnancy (from 30 weeks gestation) and during labor due to the NSAID component. Official regulatory information typically notes that use during breastfeeding requires consideration of potential risks.

Q: What are the requirements for monitoring (like blood tests) while using Ultrabengue?

A: Official regulatory documents note that monitoring of renal (kidney) function is typically required in patients with pre-existing kidney or liver impairment. Other monitoring, such as blood pressure or complete blood count, may be recommended for certain patient groups or with prolonged use.

Q: What is the primary ingredient in Ultrabengue?

A: Ultrabengue is a combination medicine that works through multiple components, so it does not have a single primary ingredient. It contains four active agents: the NSAID Naproxen Sodium, the local anesthetic Lidocaine Hydrochloride, and the counter-irritants Menthol and Methyl Salicylate.

Q: Is Ultrabengue prescribed for more than one medical issue?

A: The product is officially approved for the temporary relief of localized pain and inflammation. Clinical studies have focused on its use for mild-to-moderate osteoarthritis of the knee, but its general purpose covers localized pain management for the muscles, joints, and soft tissues.

Q: Does Ultrabengue impact the immune system?

A: The drug's mechanism of action involves inhibiting prostaglandins and modulating a key molecular pathway called NF-kappaB. This regulation of signaling is how the medicine controls inflammation and pain signals at the local tissue level, thereby influencing the localized immune/inflammatory response.

Q: Is Ultrabengue effective for managing all symptoms of the condition it treats?

A: Regulatory reviews of clinical studies focus on measured outcomes, such as pain and stiffness scores. The evidence supports the product's use for those specific symptoms, but the documentation does not contain a comprehensive claim for managing all possible symptoms.

Q: Is it necessary to have certain tests before starting Ultrabengue?

A: Official prescribing information indicates that pre-treatment tests, such as those checking kidney or liver function, may be necessary if a patient has pre-existing renal or hepatic impairment.

Q: What happens if I miss a scheduled time for Ultrabengue?

A: Official administration guidelines include instructions for handling a missed dose. These instructions are designed to maintain a consistent treatment schedule and generally advise against applying a double dose to make up for a missed one.

Q: Can Ultrabengue cause trouble sleeping or change my energy level?

A: Official documents for the NSAID component (Naproxen) note possible central nervous system effects. These can include difficulty falling asleep (insomnia), feeling tired, or drowsiness. Any persistent change in sleep or energy should be reported.

Q: Can a person stop using Ultrabengue suddenly, or does it need to be tapered?

A: Since the product is typically used for short-term pain, stopping the topical NSAID component suddenly does not usually cause physiological withdrawal symptoms that necessitate a taper. Discontinuation or changes to the treatment plan are details that should be confirmed against a prescribed regimen.

Q: Does Ultrabengue make you more sensitive to sunlight?

A: The NSAID component (Naproxen) is known in regulatory documents to cause photosensitivity, which is an increased sensitivity to the sun. Official guidance notes that due to the risk of photosensitivity, patients may need to limit prolonged or excessive exposure to sunlight and artificial UV light while using the medicine.

Q: Does Ultrabengue have any known interactions with herbal supplements or vitamins?

A: Official labeling advises patients to always inform their healthcare provider of all other medications, including over-the-counter medicines, vitamins, and herbal supplements. This is necessary because formal interaction data for every combination of medicine and supplement may not be available.

Q: Does Ultrabengue cause weight gain or loss?

A: Official information for the NSAID component (Naproxen) does not list weight gain or loss as a direct side effect. However, it can cause fluid retention and edema (swelling), and any associated increase in body weight is typically noted in a patient's medical records.

Q: Is Ultrabengue considered a controlled substance?

A: Ultrabengue is classified as a Topical Analgesic and Anti-inflammatory Agent. None of its active ingredients—Naproxen Sodium, Lidocaine Hydrochloride, Menthol, or Methyl Salicylate—are classified as controlled substances by the US Drug Enforcement Administration.

Q: Are the side effects of Ultrabengue permanent?

A: The vast majority of side effects reported in clinical trials, such as application site reactions, headache, and nausea, are temporary. Official documents describe these adverse events as generally resolving upon the discontinuation of the medicine.

Q: What do official sources say about Ultrabengue's impact on mood?

A: Official product information for the NSAID component (Naproxen) is occasionally associated with psychiatric or central nervous system effects. This can include rare reports of confusion, nervousness, or certain mood changes.

Q: Is it safe to drink a small amount of alcohol while using Ultrabengue?

A: Regulatory documents explicitly caution that the use of alcohol increases the risk of serious gastrointestinal bleeding associated with the NSAID component. Official guidance does not define or endorse 'small amounts' as safe for consumption while using the medicine.

How should Ultrabengue be stored and disposed of?

How to Store and Dispose of Ultrabengue

Ultrabengue must be stored according to specific regulatory requirements to maintain its stability and effectiveness. The official labeled instructions define three core requirements for storage and handling.

Storage and Stability

Temperature: Store at controlled room temperature, typically between 20 C and 25 C. Do not freeze the medication at any time.
Protection: Keep the product in its original container and carton to protect it from light and moisture. The container cap must be tightly closed after use.
In-Use Stability: Any solution reconstituted from the powder must be used within 24 hours. If not used immediately, the reconstituted solution should be refrigerated.

Disposal Requirements

Unused Product: Dispose of any unused, expired, or unwanted medicine through an official drug take-back program or an authorized collection site.
Wastewater: Do not flush Ultrabengue down the toilet or pour it into a drain unless regulatory guidance explicitly instructs you to do so.
Safety: The product must always be stored out of the reach and sight of children.

Ultrabengue